Current Clinical Trials
All Open Trials | Open Cancer Trials | Open HIV Trials
| Title | Trial ID# | Disease Indication | Cell-Biologic Product | Principal Investigator |
|---|---|---|---|---|
| Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia (NCT02650414) | 15CT055 | Pediatric ALL | Autologous CD22-CAR T cells | Stephan Grupp, MD, PhD |
| Phase 2 Trial of CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T cells (CART19) for Orphan Indications of Pediatric B cell Acute Lymphoblastic Leukemia (B-ALL) (NCT04276870) | 19CT023 | Pediatric ALL, Orphan Indications | murine CART19 | Amanda DiNofia, MD |
| Combination therapy with CART22-65(s) With huCART19 in Pediatric Relapsed and Refractory B-Acute Lymphoblastic Leukemia (ALL) (NCT05674175) | 22CT015 | Pediatric B-ALL | CART22-65s/hu-CART19 | Regina Meyers, MD |
| Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory Neuroblastoma (NCT05650749) | 22CT012 | Pediatric Neuroblastoma | GPC2 CAR T Cell | Lisa Wray, MD |
| Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney Transplantation (NCT06056102) | CTOT-46 | Patients Awaiting Kidney Transplantation | CART-BCMA huCART19 |
Vijay Bhoji, MD, PhD |
| A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma (NCT05568680) | STAR-101 | Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma | SynKIR-110 | |
| Phase I, Open-Label Study of Dually Armored Chimeric Antigen Receptor (CAR) T Cells (TmPSMA-02) in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (NCT06046040) | UPCC11823 | Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | TmPSMA-02 CAR T | Vivek Narayan, MD |
| Phase I Trial of TmCD19-IL18 CAR T Cells in Patients with Relapsed orRefractory CD19+ CancersIND (NCT05989204) | UPCC12423 | Relapsed or Refractory CD19+ Cancers | TMhuCAR19 | Jakub Svoboda, MD |
| CVPF research Apheresis protocol only | UPCC36908 | Multiple Clinical Trials | Apheresis product | Andrew Fesnak, MD, PhD |
| Phase 1 Open-label Study Evaluating the Safety of CART-EGFR-IL13Rα2 Cells in Patients With Newly Diagnosed, EGFR-Amplified, MGMT-unmethylated Glioblastoma Following Completion of Initial Radiotherapy (NCT06973096) | UPCC03325 | Glioblastoma | CART-EGFR-IL13Ra2 | Stephen Bagley, MD, MSCE |
| Phase Ib, Open-Label Study of CART-EGFR-IL13Rα2 Cells Administered Following Lymphodepleting Chemotherapy or Prior to Surgical Resection in Patients With EGFR-Amplified Recurrent Glioblastoma (NCT07209241) | UPCC10325 | EGFR-Amplified Recurrent GBM | CART-EGFR-IL13Ra2 | Stephen Bagley, MD, MSCE |
| Phase I Trial of CART123 cells given combination with Ruxolitinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) (NCT06768476) | UPCC50424 | AML | CART123 | Saar Gill, MD, PhD |
Contact Us
Clinical Cell and Vaccine Production Facility (CVPF)
Center for Advanced Cellular Therapies
9th Floor SPE/South Tower, Bldg. 421
3400 Civic Center Boulevard
Philadelphia, PA 19104
